What’s New: Sankara Eye Foundation and Singapore-based Leben Care are deploying a comprehensive retina risk assessment software-as-a-service platform in India. Netra.AI, the cloud-based artificial intelligence (AI) solution, is powered by Intel® technology and uses deep learning to identify retinal conditions in a short span of time with the accuracy level of human doctors. Netra.AI can accurately identify diabetic retinopathy (DR), greatly reducing the screening burden on vitreoretinal surgeons.
“The use of AI to improve disease detection and prevention is a critical step for the healthcare industryand a giant leap for humankind. India has one of the largest diabetic populations in the world and diabetic retinopathy is the major cause for vision loss and blindness in persons of working age. With Netra.AI, Sankara Eye Foundation and Leben Care have leveraged the power of Intel® Xeon® Scalable processors and built-in Intel® Deep Learning (DL) Boost to accurately detect DR and enable timely treatment to effectively combat avoidable vision impairment and blindness in diabetic patients.”
–Prakash Mallya, vice president and managing director of Sales, Marketing and Communications Group, Intel India
of any country in the world, approaching 98 million cases by 2030.1 Research shows that DR is a leading cause of blindness and vision loss in adults, andearly detection andtreatment is critical to stopping the damage. However, the lack of trained retinal specialists in India — especially in remote, rural regions — limits effective screening of asymptomatic patients. This results in patients presenting late with advanced diabetic eye disease. “Technology and AI are democratizing healthcare access, especially in screening for ailments,” said Dr. Kaushik Murali, president of Medical Administration, Quality & Education, Sankara Eye Foundation India. “Our team at Sankara Eye Foundation has focused on our vision to eliminate needless blindness from India. The current solution, Netra.AI — where we had a key role in the design and development with Leben Care — uses robust AI-enabled platforms from Intel. It is an example of how like-minded collaborators can create meaningful and impactful solutions for various challenges that face humanity.”
More Context: Harnessing AI to Transform Diabetic Retinopathy Diagnosis and Treatment (Case Study) | Intel Health and Life Sciences | Artificial Intelligence at Intel
The Small Print:
1 https://www.eurekalert.org/pub_releases/2018-11/tl-tld111918.php